Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.

You may also be interested in...

FDA Wants Another Trial Of Genta’s Genasense For CLL

FDA’s complete response letter requesting another trial concludes the agency’s review of an amended NDA submitted after an unsuccessful appeal of a “not approvable” letter.

Gilead Hopes To Dodge New Trial With CF Antibiotic

FDA’s complete response finds the Cayston NDA not approvable as is.

Labopharm Submits Complete Response For Tramadol

Canadian specialty pharma now awaits new action date for delayed once-daily analgesic, already launched in 12 other countries.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts